Latest Market Expansion News

First Graphene has demonstrated a significant carbon reduction in cement roof tiles through a UK production trial with FP McCann, using graphene-enhanced cement to lower emissions and material use.

ikeGPS Group delivered a strong FY26 with platform subscription revenue up 33% to NZ$19.2 million and positive underlying EBITDA in March, supported by AI-driven pricing and expanding US utility adoption.

Airtasker Limited posted robust 3Q26 results highlighted by strong Australian marketplace momentum and explosive growth in the UK and US. The company reaffirmed its FY26 guidance, underpinned by strategic media partnerships and a solid cash position.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Bioxyne Limited posted a record $21.3 million revenue in Q3 FY26, driven by strong demand for medicinal cannabis and psychedelics. The company secured a manufacturing agreement with Aurora Cannabis and initial orders for GMP psilocybin capsules, reaffirming FY26 guidance.

Vitura Health’s telehealth arm, Doctors on Demand, has hit a major milestone of over 1 million consultations since FY2024, while delivering sustained EBITDA profitability and a 54% revenue increase over two years to $21.6 million in FY2026 Q1-Q3.

AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Navigator Global Investments (ASX: NGI) reported a 9% jump in ownership-adjusted assets under management to USD31.6 billion for Q3 FY26, driven by strong inflows, strategic acquisitions, and solid hedge fund performance amid market volatility.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Love Group Global Ltd reported a 15% decline in quarterly customer cash receipts to $884k in Q3 FY26, driven by a sharp drop in Hong Kong. Despite this, the company maintained positive net operating cash flow and is pursuing growth in US and UK markets.

Comvita launches a NZ$30 million renounceable Rights Offer to refinance debt and bring Southeast Asian consumer giant Fraser and Neave onboard as a strategic investor with a near 20% stake.